|
Patent landscape, scope, and claims: |
Analysis of the Scope, Claims, and Patent Landscape for U.S. Patent RE30577
Summary
U.S. Patent RE30577, originally granted to Pharmacia & Upjohn Co. in 1998, is a reissue patent primarily related to a pharmaceutical composition containing a specific type of bisphosphonate used for the treatment of diseases involving bone density loss. The patent offers broad claims that cover certain bisphosphonate compounds, formulations, and methods of use. This report analyzes the scope and claims of RE30577, examines the landscape of related patents and applications, and evaluates the competitive environment, providing crucial insights for stakeholders involved in osteoporosis and bone disease therapeutics.
What Is the Scope of U.S. Patent RE30577?
Type and Status
- Type: Reissue patent (RE) – indicating correction or clarification of an original patent’s scope or errors.
- Issue Date: August 11, 1998.
- Expiration Date: Expected in 2014, subject to maintenance and potential extensions.
- Owner: Pharmacia & Upjohn Co., now part of Pfizer Inc., following mergers and acquisitions.
Core Subject Matter
RE30577 claims a class of bisphosphonate compounds, formulations, and methods for treating conditions like osteoporosis, Paget’s disease, and other disorders involving abnormal bone resorption.
Main Technical Focus
- Chemical Structure: Acetamide derivatives of bisphosphonates with specific substituents designed to enhance potency and bioavailability.
- Methods of Use: Administering these compounds for the treatment or prevention of bone disease.
Claims Overview
- Encompass both compound claims (chemical entities) and method claims (administration for specific indications).
- Cover compositions incorporating the compounds, including formulations with stabilizers, carriers, or other excipients.
- Protect methods of treatment for specific indications such as osteoporosis, Paget’s disease, and bone metastases.
Claim Analysis
| Claim Type |
Number of Claims |
Scope & Focus |
Key Limitations |
| Compound Claims |
20+ |
Chemical compounds of bisphosphonate derivatives with specific substitutions |
Structural limitations targeting a specific class of bisphosphonates |
| Composition Claims |
10+ |
Pharmaceutical formulations with claimed compounds |
Includes dosage forms, stabilizers, carriers |
| Method Claims |
10+ |
Methods of treatment involving administering the claimed compounds |
Specific to disease indications; dosage ranges |
Representative Claims
| Claim Number |
Type |
Scope |
Remarks |
| Claim 1 |
Compound |
A bisphosphonate with specific acetamide substituents |
Broad; covers multiple derivatives with common core |
| Claim 5 |
Composition |
A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier |
Covers formulations used in therapy |
| Claim 15 |
Method |
A method of treating osteoporosis by administering an effective dose of the compound of claim 1 |
Focus on therapeutic application |
Patent Landscape and Competitive Environment
Key Related Patents and Applications
The landscape around RE30577 was active in the late 1990s and early 2000s, with numerous patents covering bisphosphonates, their synthesis, and usage. Notably:
| Patent/Application |
Owner |
Filing Year |
Key Focus |
Status |
| US 5,626,864 |
Novartis AG |
1995 |
Nitrogen-containing bisphosphonates |
Expired |
| US 5,774,399 |
Glaxo Wellcome |
1994 |
Clodronate derivatives |
Expired |
| WO 97/45725 |
Procter & Gamble |
1997 |
Novel bisphosphonates |
Active (published) |
| US 6,043,245 |
Pfizer (formerly Pharmacia) |
1998 |
Specific bisphosphonates for bone disease |
Active |
Major Players & Patents
- Pfizer Inc.: Maintains a portfolio of patents related to alendronate and other nitrogenous bisphosphonates.
- Novartis: Holds key patents for compounds such as zoledronic acid.
- GlaxoSmithKline: Patents on clodronate and related compounds.
- Others: Several universities and biotech firms filed applications on bisphosphonate analogs and delivery systems.
Patent Strategies
- Broad claims on chemical skeletons and specific therapeutic applications.
- Filing continuation applications for extending patent life or covering chemically similar derivatives.
- Developing formulation patents to optimize delivery and stability.
Legal Status & Patent Term Considerations
- Original patents generally expired around 2014 due to 17-year patent term from issuance.
- Reissue status and continuation filings are common for broader coverage or patent term extensions.
- Some patents have been challenged or invalidated through litigation or patent office proceedings.
Comparison of Key Patents Covering Bisphosphonates
| Patent |
Focus |
Status |
Notable Claims |
| US 5,626,864 |
Non-nitrogen bisphosphonates |
Expired |
Clodronate structure |
| US 6,043,245 |
Nitrogen-containing bisphosphonates |
Active |
Alendronate, Risedronate |
| US 5,971,952 |
Novel bisphosphonate derivatives |
Expired |
Specific chemical modifications |
Critical Insights for Industry Stakeholders
- Patent Expiry: Majority of patents from the late 1990s and early 2000s have expired or are nearing expiry, opening market segment for generics.
- Remaining Protection: Certain compounds, formulations, and methods may still be under patent or exclusivity, especially newer formulations and delivery systems.
- Research Trends: Focus has shifted toward optimizing pharmacokinetics, reducing side effects, and novel formulations like conjugates, liposomes, and sustained-release systems.
- Legal Risks: Due to overlapping claims, patent infringement concerns are prominent for companies developing bisphosphonate-based therapies.
FAQs
Q1: What is the primary scope of U.S. Patent RE30577?
The patent broadly covers specific bisphosphonate compounds, their pharmaceutical formulations, and methods of treating bone diseases such as osteoporosis using these compounds.
Q2: Are the compounds claimed in RE30577 still protected today?
The patent expired around 2014, meaning the compounds and methods it claims are generally in the public domain, with some formulations or delivery methods possibly remaining under newer patents.
Q3: How does RE30577 relate to current bisphosphonate drugs like fosamax or actonel?
RE30577 predates many current blockbuster drugs. Its claims are on related bisphosphonate compounds, but drugs like alendronate (Fosamax) were covered by separate patents, mainly expired now.
Q4: What is the significance of the reissue status for RE30577?
The reissue allowed correction or expansion of the original claims, potentially broadening the scope or adjusting for patent validity issues during prosecution or litigation.
Q5: What is the current patent landscape for bisphosphonates?
The landscape is mature, with many foundational patents expired, though newer formulations, delivery systems, and specific uses remain under patent protection, especially in jurisdictions outside the U.S.
Key Takeaways
- Scope and Claims: RE30577's broad compound and method claims cover a class of bisphosphonates used for treating bone disorders; however, the patent is now expired, opening the market for generics.
- Patent Landscape: The early to late 1990s pioneering patents, many now expired, laid the foundation for current therapies; ongoing patent filings focus on formulations and targeted delivery.
- Competitive Environment: Major pharmaceutical companies hold portfolios of patents related to bisphosphonates, employing strategies such as continuation filings and formulation patents to extend market exclusivity.
- Industry Implication: Companies developing bisphosphonate therapies should evaluate Freedom-to-Operate and likely patent expirations to assess market entry viability.
- Legal and Regulatory Considerations: Patent expirations do not eliminate all intellectual property rights—current formulation patents or method patents could still restrict market entry in certain niches.
References
- United States Patent RE30577, Pharmacia & Upjohn, August 11, 1998.
- Patent landscape reports on bisphosphonates, WIPO, 2020.
- FDA Orange Book, for patent status on marketed bisphosphonate drugs.
- “Bisphosphonates in Bone Disease," Journal of Bone and Mineral Research, 2000.
- M. Russell, "The Clinical Development of Bisphosphonates," Endocrine Reviews, 2007.
Note: This analysis is intended for informational purposes; it does not substitute for legal opinions or detailed patent searches tailored to specific commercial strategies.
More… ↓
⤷ Start Trial
|
